<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120701</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 70 - CIRCULATE</org_study_id>
    <nct_id>NCT04120701</nct_id>
  </id_info>
  <brief_title>CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II</brief_title>
  <acronym>CIRCULATE</acronym>
  <official_title>CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of CIRCULATE trial is to improve care of patients after colon tumor surgery,&#xD;
      based on an innovative marker: circulating tumor DNA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2020</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year Disease-Free Survival in ctDNA positive patients</measure>
    <time_frame>3-years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1980</enrollment>
  <condition>Patients With Resected Stage II Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up within the study</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow-up outside the study</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6</intervention_name>
    <description>Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent obtained prior to any study specific procedures&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 75 years&#xD;
&#xD;
          -  Histologically confirmed stage II colon and high rectum adenocarcinoma excluding low&#xD;
             and medium rectal cancers (tumor location ≥ 12 cm from the anal verge by endoscopy&#xD;
             and/or above the peritoneal reflection at surgery are still eligible), without gross&#xD;
             or microscopic evidence of residual disease after surgery with curative intent.&#xD;
             Pathology report must be faxed to CRGA just after patient's randomization.&#xD;
&#xD;
          -  At least 12 lymph nodes analyzed&#xD;
&#xD;
          -  Patient with MSI + tumors can be included&#xD;
&#xD;
          -  All patients must have been discussed in multidisciplinary meetings with a decision of&#xD;
             not performing adjuvant chemotherapy&#xD;
&#xD;
          -  No metastatic disease on CT-Scan and/or liver MRI done within 3 months before&#xD;
             randomization.&#xD;
&#xD;
          -  Randomization planned up to 7 weeks after curative R0 resection&#xD;
&#xD;
          -  WHO performance Status &lt; 2&#xD;
&#xD;
          -  No prior chemotherapy for colo-rectal cancer&#xD;
&#xD;
          -  No prior abdominal or pelvic irradiation for colo-rectal cancer&#xD;
&#xD;
          -  Life expectancy of ≥ 5 years&#xD;
&#xD;
          -  Adequate haematological function: with neutrophils ≥ 1,500 /mm3, platelet count ≥&#xD;
             100,000/mm3, hemoglobin ≥ 9 g/dL (5,6 mmol/l)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN (upper limit of normal)&#xD;
&#xD;
          -  ASAT and ALAT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 120 µmol/L or creatinine clearance ≥50 ml/min according MDRD&#xD;
             (Modification of Diet in Renal Disease)&#xD;
&#xD;
          -  Carcinoembryogenic antigen (CEA) ≤ 1.5 x ULN after surgery (during screening period)&#xD;
&#xD;
          -  Negative pregnancy test for registration(for women of childbearing age)&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T4b tumors&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Comorbidity influencing the 5 year patients' survival including clinically relevant&#xD;
             cardiovascular disease,&#xD;
&#xD;
          -  Ischemic myocardial infarction in the last year and/or unstable ischemic cardiopathy,&#xD;
&#xD;
          -  Participation to another interventional study for postoperative therapy&#xD;
&#xD;
          -  Partial or complete DPD deficiency&#xD;
&#xD;
          -  Legal incapacity or physical, psychological social or geographical status interfering&#xD;
             with the patient's ability to sign the informed consent or to finish the study&#xD;
&#xD;
          -  Medical history of other concomitant or previous malignant disease, except adequately&#xD;
             treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of&#xD;
             the skin, or cancer in complete remission for ≥ 5 years,&#xD;
&#xD;
          -  Lack of effective contraception in patients (men and/or women) of childbearing age,&#xD;
             pregnant or breastfeeding women. Women of childbearing potential should agree to use a&#xD;
             method of contraception during treatment of the trial and at least 4 months after&#xD;
             discontinuation of oxaliplatin therapy and at least 30 days after discontinuation of&#xD;
             5-fluorouracil. Men must agree to use a method of contraception during treatment and&#xD;
             at least 6 months after stopping oxaliplatin therapy and at least 3 months after&#xD;
             stopping 5-fluorouracil.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julien TAIEB</last_name>
    <phone>+33 1 56 09 50 42</phone>
    <email>julien.taieb@egp.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fédération Francophone de Cancérologie Digestive</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flore GEILLON</last_name>
      <phone>+33 3 80 39 34 04</phone>
      <email>flore.geillon@u-bourgogne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

